Amneal Pharmaceuticals (AMRX) Revenue & Revenue Breakdown
Amneal Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$2.79B
Latest Revenue (Q)
$702.47M
Main Segment (Y)
Specialty Segment
Main Geography (Y)
Specialty Segment
Amneal Pharmaceuticals Revenue by Period
Amneal Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $2.79B | 16.73% |
| 2023-12-31 | $2.39B | 8.20% |
| 2022-12-31 | $2.21B | 5.67% |
| 2021-12-31 | $2.09B | 5.08% |
| 2020-12-31 | $1.99B | 22.51% |
| 2019-12-31 | $1.63B | -2.20% |
| 2018-12-31 | $1.66B | 60.88% |
| 2017-12-31 | $1.03B | 1.52% |
| 2016-12-31 | $1.02B | 17.54% |
| 2015-12-31 | $866.28M | 10.27% |
| 2014-12-31 | $785.62M | - |
Amneal Pharmaceuticals generated $2.79B in revenue during NA 2024, up 16.73% compared to the previous quarter, and up 171.79% compared to the same period a year ago.
Amneal Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $702.47M | 0.10% |
| 2024-06-30 | $701.78M | 6.46% |
| 2024-03-31 | $659.19M | 6.84% |
| 2023-12-31 | $616.98M | -0.49% |
| 2023-09-30 | $620.04M | 3.50% |
| 2023-06-30 | $599.05M | 7.44% |
| 2023-03-31 | $557.54M | -8.56% |
| 2022-12-31 | $609.76M | 11.77% |
| 2022-09-30 | $545.56M | -2.47% |
| 2022-06-30 | $559.36M | 12.40% |
| 2022-03-31 | $497.63M | -7.31% |
| 2021-12-31 | $536.90M | 1.57% |
| 2021-09-30 | $528.59M | -1.21% |
| 2021-06-30 | $535.08M | 8.51% |
| 2021-03-31 | $493.11M | -3.32% |
| 2020-12-31 | $510.03M | -1.78% |
| 2020-09-30 | $519.29M | 11.76% |
| 2020-06-30 | $464.66M | -6.79% |
| 2020-03-31 | $498.53M | 25.47% |
| 2019-12-31 | $397.33M | 5.03% |
| 2019-09-30 | $378.28M | -6.51% |
| 2019-06-30 | $404.64M | -9.30% |
| 2019-03-31 | $446.12M | -10.33% |
| 2018-12-31 | $497.53M | 4.42% |
| 2018-09-30 | $476.49M | 15.15% |
| 2018-06-30 | $413.79M | 50.36% |
| 2018-03-31 | $275.19M | -6.20% |
| 2017-12-31 | $293.37M | 15.17% |
| 2017-09-30 | $254.73M | -1.98% |
| 2017-06-30 | $259.87M | 15.15% |
| 2017-03-31 | $225.68M | -24.41% |
| 2016-12-31 | $298.58M | - |
Amneal Pharmaceuticals generated $702.47M in revenue during Q3 2024, up 0.10% compared to the previous quarter, and up 117.26% compared to the same period a year ago.
Amneal Pharmaceuticals Revenue Breakdown
Amneal Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Specialty Segment | $445.75M | $390.46M | - | - | - |
| Generics Segment | - | $1.47B | $1.43B | $1.37B | $1.34B |
| Amneal Specialty Pharma Segment | - | - | $374.12M | $378.32M | $355.57M |
| Av K A R E Segment | - | - | $406.11M | - | - |
| Av Kare | - | - | - | $349.01M | $293.75M |
Amneal Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Specialty Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Specialty Pharma Segment | $115.64M | $105.23M | $96.99M | $91.68M | $102.55M | $89.48M | $97.00M | $85.09M | $101.01M | $92.75M | $95.93M | $85.47M | $87.87M | $94.26M | $97.05M | - | - | - | - | - |
| Generics Segment | $427.35M | $391.29M | $753.89M | $373.70M | $343.81M | $399.17M | $350.27M | $364.89M | $317.75M | $346.27M | $347.13M | $360.44M | $312.51M | $342.14M | $341.92M | $306.56M | $985.00K | $300.28M | - | - |
| Av K A R E Segment | - | - | - | $128.35M | $122.06M | $108.04M | $105.81M | $97.46M | $94.80M | $88.72M | $86.00M | $84.67M | $89.51M | $63.85M | $57.97M | - | - | - | - | - |
| Specialty Segment | - | - | - | - | - | - | - | - | - | - | - | $88.64M | $87.98M | - | - | - | - | - | - | - |
| Rytary Family | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $33.71M | $33.00M |
| Diclofenac Sodium Gel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $19.26M | $25.01M |
| Epinephrine Auto Injector Family Generic Adrenaclick | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $22.69M | - |
| Levothyroxine Sodium | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $39.77M | $46.46M |
| Oxymorphone | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $17.14M | - |
| Yuvafem-Estradiol | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.02M |
| Epinephrine Auto-Injector Family (Generic Adrenaclick) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.96M |
Amneal Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Generics Segment (78.70%), and Amneal Specialty Pharma Segment (21.30%).
Amneal Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Specialty Segment | $445.75M | $390.46M | $374.12M | $378.32M | $355.57M |
| Generics Segment | - | $1.47B | $41.09M | $35.97M | $37.39M |
Amneal Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: Specialty Segment (100.00%).
Quarterly Revenue by Country
| Country | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Segment | $224.88M | $115.64M | $105.23M | $201.78M | $96.99M | $91.68M | $102.55M | $89.48M | $97.00M | $85.09M | $101.01M | $92.75M | $88.64M | $95.93M | $85.47M | $87.87M | $94.26M | $87.98M | - | - |
| Generics Segment | - | $427.35M | $391.29M | $1.45B | $11.14M | $12.81M | $14.58M | $8.72M | $12.12M | $5.67M | $9.09M | $8.23M | $10.46M | $8.18M | $9.19M | $10.88M | $7.24M | $985.00K | $300.28M | $291.02M |
Amneal Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 24: Specialty Segment (100.00%).
Amneal Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMRX | Amneal Pharmaceuticals | $2.79B | $702.47M |
| NBIX | Neurocrine Biosciences | $2.36B | $622.10M |
| ALKS | Alkermes | $1.56B | $378.14M |
| PAHC | Phibro Animal Health | $977.89M | $309.26M |
| AMPH | Amphastar Pharmaceuticals | $712.81M | $188.82M |
| ITCI | Intra-Cellular Therapies | $680.85M | $175.38M |
| COLL | Collegium Pharmaceutical | $631.45M | $159.30M |
| ANIP | ANI Pharmaceuticals | $614.38M | $148.33M |
| PROC | Procaps Group | $409.92M | $118.41M |
| IRWD | Ironwood Pharmaceuticals | $351.41M | $91.59M |
| DVAX | Dynavax | $277.25M | $79.34M |
| EOLS | Evolus | $264.31M | $60.16M |
| LFCR | Lifecore Biomedical | $128.26M | $35.15M |
| ASRT | Assertio | $124.96M | $29.20M |